Feedback
Settings

Settings

Goto Application

1,877 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(RVCNQQGZJWVLIP-VPCXQMTMSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 188
1.WO/2025/264648COMPOSITIONS AND METHODS FOR MODULATING NATIVE HUMAN MRNA EXPRESSION
WO - 26.12.2025
Int.Class A61K 47/69
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
 Appl.No PCT/US2025/033940 Applicant GRANN PHARMACEUTICALS INC. Inventor TEMPLE, Thomas Lyle
In certain aspects, provided herein are therapeutic composition comprising a native human mRNA formulated in a lipid nanoparticle (LNP), wherein the mRNA comprises an open reading frame encoding native human mRNA, and methods of using the same.
2.WO/2025/264882ENZYMATIC SYNTHESIS OF NTP AND 3'-PHOSPHORYLATED NUCLEOTIDES
WO - 26.12.2025
Int.Class C12P 19/30
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
 Appl.No PCT/US2025/034294 Applicant CODEXIS, INC. Inventor BERMUDEZ, Ericka
The present disclosure provides enzymatic methods for the production of 3'-phosphatenucleoside-5'-triphosphate (NQP). The present disclosure further provides enzymatic methods for the production of nucleotide-5'-triphosphates. In some embodiments, a method of producing a nucleotide triphosphate with a phosphate group at the 3' position of the sugar moiety (NQP), the method comprising at least: contacting a nucleoside diphosphate (NDP) with a nucleoside diphosphate kinase, a 3' -O-kinase, and a phosphate donor under reaction conditions such that a NTP with a phosphate group on the 3' position of the sugar moiety (NQP) is produced.
3.WO/2025/255168MODIFIED CAS12 GUIDES AND USES THEREOF
WO - 11.12.2025
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/US2025/032145 Applicant PIONEER HI-BRED INTERNATIONAL, INC. Inventor MAY, Andrew Paul
Disclosed herein are compositions, kits methods related to improved Cas12 systems, specifically including Cas12 guide RNAs. In particular, the present disclosure provides insights and technologies relating to Cas12f systems.
4.1020250172722키랄 디자인
KR - 09.12.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No 1020257039389 Applicant 웨이브 라이프 사이언시스 리미티드 Inventor 미나 미나
본 발명은 선택 디자인의 키랄 제어된 올리고뉴클레오티드, 키랄 제어된 올리고뉴클레오티드 조성물, 및 이를 제조 및 이용하는 방법에 관한 것이다. 일부 구현예에서, 제공된 키랄 제어된 올리고뉴클레오티드 조성물은 레퍼런스 올리고뉴클레오티드 조성물과는 상이한 핵산 중합체의 절단 패턴을 제공한다. 일부 구현예에서, 제공된 키랄 제어된 올리고뉴클레오티드 조성물은 핵산 중합체의 상보적 서열 내 단일의 절단 부위를 제공한다.
5.1020250168315ROSA26 세이프 하버 부위에서의 녹인 전략
KR - 02.12.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No 1020257034032 Applicant 에멘도바이오 인코포레이티드 Inventor 엠마누엘 라피
서열번호 1-25686 중 어느 하나에 제시된 서열의 17-50개의 연속 뉴클레오티드를 갖는 가이드 서열 부분을 포함하는 RNA 분자 및 이의 조성물, 방법 및 용도.
6.1020250166362RNA 간섭을 위한 이중 가닥 올리고뉴클레오티드 조성물 및 이와 관련된 방법
KR - 27.11.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No 1020257030816 Applicant 웨이브 라이프 사이언시스 리미티드 Inventor 바기즈 챈드라
본 개시는 이중 가닥 올리고뉴클레오티드, 조성물 및 이와 관련된 방법을 제공한다. 본 개시는 염기 서열, 화학적 변형(예: 당, 염기 및/또는 뉴클레오티드 간 결합의 변형) 또는 이의 패턴 및/또는 입체화학(예: 백본 키랄 중심(키랄 뉴클레오티드간 결합)의 입체화학) 및/또는 이의 패턴과 같은 이중 가닥 올리고뉴클레오티드의 구조적 요소가 올리고뉴클레오티드 특성 및 활성, 예를 들어 RNA 간섭(RNAi) 활성, Ago2 로딩, 열 안정성, 생체 내 안정성, 조직 및 세포로의 전달 등에 상당한 영향을 미칠 수 있다는 인식을 포함한다. 본 공개는 또한 제공된 이중 가닥 올리고뉴클레오티드 조성물을 사용하여 예를 들어 RNA 간섭에서 간 질환, 중추 신경계(CNS) 질환 등의 질병을 치료하는 방법을 제공한다.
7.1020250166303폴리(A)를 포함하는 폴리뉴클레오타이드 분자 및 이의 용도
KR - 27.11.2025
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No 1020257036108 Applicant 센젠 센신 바이오테크놀로지 컴퍼니 리미티드 Inventor 황, 후이
적어도 30개의 뉴클레오타이드를 갖는 변형된 폴리(A)를 포함하는 폴리뉴클레오타이드가 제공된다. 변형된 폴리(A)는 i) A 뉴클레오타이드로 이루어진 폴리뉴클레오타이드로서 정의되는 적어도 2개의 R 요소; 및 ii) 적어도 하나의 S 요소를 포함한다. S 요소는 a) A 뉴클레오타이드 이외의 뉴클레오타이드이거나, b) 적어도 2개의 뉴클레오타이드로 이루어지며, 양쪽 단부의 뉴클레오타이드는 A 뉴클레오타이드가 아니다. S 요소의 총 수는 R 요소의 총 수보다 1개 더 적고, S 요소는 R 요소에 연결되고, S 요소 각각은 R 요소에 의해 플랭킹된다. 본 발명은 또한, 폴리뉴클레오타이드를 포함하는 벡터 및 숙주 세포, RNA를 제조하기 위해 폴리뉴클레오타이드를 사용하는 방법 및 이로부터 제조되는 RNA, 폴리뉴클레오타이드, RNA, 벡터, 및/또는 숙주 세포를 포함하는 약학적 조성물 또는 LNP, 및 이의 용도에 관한 것이다.
8.1020250162839AAVS1 세이프 하버 부위에서의 녹인 전략
KR - 19.11.2025
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No 1020257034274 Applicant 에멘도바이오 인코포레이티드 Inventor 엠마누엘 라피
서열번호 1-24195 중 어느 하나에 제시된 서열의 17-50개의 연속 뉴클레오티드를 갖는 가이드 서열 부분을 포함하는 RNA 분자 및 이의 조성물, 방법 및 용도.
9.20250346908FLUOROGENIC NUCLEOSIDES
US - 13.11.2025
Int.Class C12N 15/115
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
 Appl.No 18869037 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor Jonathan Rittichier

Provided herein are Anorogenic nucleosides (e.g., Anorogenic nucleoside triphosphates (NTPs), e.g., Anorogenic reversible terminator nucleoside triphosphates) which can be used in the synthesis of Anorogenic oligonucleotides (e.g., Anorogenic DNA or RNA oligonucleotides, such as Anorogenic RNA aptamers). The Anorogenic oligonucleotides (e.g., Anorogenic DNA or RNA oligonucleotides, such as, Anorogenic RNA aptamers) can be used as Anorogenic probes to detect targets (e.g., antigens, biomarkers).

10.WO/2025/228326RECOMBINANT RNA MOLECULE AND USE THEREOF
WO - 06.11.2025
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
 Appl.No PCT/CN2025/091753 Applicant SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD. Inventor LI, Linxian
Provided are a recombinant RNA molecule and a use thereof. The recombinant RNA molecule comprises a polynucleotide encoding a polypeptide of interest and 5'-UTR and/or 3'-UTR. The recombinant RNA molecule has improved translation efficiency and/or stability; and the expression level of the polypeptide and/or protein is increased. Also provided are a vector encoding the recombinant RNA molecule, a pharmaceutical composition comprising the recombinant RNA molecule, and a method for treating or preventing a disease by using the recombinant RNA molecule.
# -